跳至主要内容
临床试验/CTRI/2019/02/017388
CTRI/2019/02/017388已完成2 期

A randomized double blind controlled trial assessing the dose response and safety of Deflazacort in boys with Duchenne muscular dystrophy - DOSE

Dr Renu Suthar0 个研究点目标入组 97 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
97

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Boys with a diagnosis of DMD: ( two should present)
  • 1With phenotypic characteristic symptoms or signs (waddling gait, Gowerâ??s sign, and calf hypertrophy)
  • 2Elevated CK, and positive genetic analysis of dystrophin gene or muscle biopsy that demonstrated a clear alteration in dystrophin amount or distribution in the muscle
  • 3.He should be ambulatory at the time of enrolment
  • 4.Baseline 6MWD should be more than 150 meters
  • 5.Steroid naive patients or who have received <6 months of any form of steroid therapy in immediate past
  • 6.Willing for functional assessment and follow up in the clinic

排除标准

  • 1.Prior long-term use of oral GCs for >6 months
  • 2.Active peptic ulcer disease or history of any gastrointestinal or perforation
  • 3.Boys with DMD and autism/ intellectual disability/ fractures
  • 4.Not willing for giving written informed consent

研究者

发起方
Dr Renu Suthar

相似试验